TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11092169

Group type: EXPERIMENTAL
Intervention: Adenosine, adenosine-receptor-agonists, and dipyridamole prior to coronary angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicorandil, an activator of the ATP-sensitive potassium channel (K-ATP channel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glibenclamide (sulfonylurea drug therapy)
Number of subjects: 0
Study: 9096687

Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone (80 mg/m2 on day 2) with cytarabine (3 g/m2 on days 1-5)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard-dose mitoxantrone (12 mg/m2 on days 1-3) with cytarabine (3 g/m2 on days 1-5)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard-dose mitoxantrone
Number of subjects: 54
Study: 8415897

Group type: EXPERIMENTAL
Intervention: 30 mg paroxetine per day
Number of subjects: 160

Group type: COMPARATOR
Intervention: 150 mg amitriptyline per day
Number of subjects: 160
Study: 3003728

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Enalapril (injection)
Number of subjects: 36
Study: 30927744

Group type: EXPERIMENTAL
Intervention: Uninterrupted sleep (US)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Forced awakenings (FA)
Number of subjects: 42
Study: 29096426

Group type: EXPERIMENTAL
Intervention: RG7342 (0.06-1.2 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RG7342 (1.2 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RG7342 (0.6 mg fasting)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RG7342 (0.9 mg fed)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RG7342
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RG7342 (MTD fasting, fed)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 27130646

Group type: EXPERIMENTAL
Intervention: Hernia repair combined with abdominoplasty
Number of subjects: 111

Group type: COMPARATOR
Intervention: Isolated incisional hernia repair
Number of subjects: 111
Study: 24612661

Group type: EXPERIMENTAL
Intervention: Celecoxib added to standard treatment
Number of subjects: 433

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 433
Study: 22511135

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation +10 cm H2O
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation +15 cm H2O
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation +5 cm H2O
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 16
Study: 20586556

Group type: EXPERIMENTAL
Intervention: Psychosomatic intervention
Number of subjects: 238

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 238
Study: 17224119

Group type: EXPERIMENTAL
Intervention: Acrylic lenses
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Silicone lenses
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hydrogel lenses
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sharp-edge designs
Number of subjects: 23

Group type: COMPARATOR
Intervention: Rounded-edge designs
Number of subjects: 23
Study: 15846273

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 12095721

Group type: EXPERIMENTAL
Intervention: PCCP
Number of subjects: 71

Group type: COMPARATOR
Intervention: DHS
Number of subjects: 71
Study: 9867078

Group type: EXPERIMENTAL
Intervention: 40 microg/kg rhIGF-I
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20 microg/kg rhIGF-I
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8561269

Group type: EXPERIMENTAL
Intervention: Topical aminosidine ointment (twice a day for two weeks)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 2520622

Group type: EXPERIMENTAL
Intervention: Cimetropium bromide 50 mg t.d.s. for 1 month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30061088

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 1505
Study: 27737654

Group type: EXPERIMENTAL
Intervention: Routine third trimester ultrasonography (two routine ultrasound examinations at 28-30 weeks and 34-36 weeks)
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Ultrasonography based on medical indication (control condition)
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Economic evaluation measuring costs from a societal perspective and quality of life using EQ-5D-5L
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Qualitative sub-study exploring ethical considerations
Number of subjects: 15000
Study: 25631687

Group type: EXPERIMENTAL
Intervention: Vitamin E‐treated highly cross‐linked polyethylene (HXLPE) liner (vitamin‐e group, n=25)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard HXLPE liner (control group, n=26)
Number of subjects: 51
Study: 23398528

Group type: EXPERIMENTAL
Intervention: Healthy diet
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 200
Study: 21211010

Group type: EXPERIMENTAL
Intervention: Prone ventilation
Number of subjects: 1675
Study: 18712776

Group type: EXPERIMENTAL
Intervention: CACE modelling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covariates predicting compliance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 0
Study: 16470370

Group type: EXPERIMENTAL
Intervention: Fully automatic diagnostic system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Visual inspection by experts
Number of subjects: 20

Group type: COMPARATOR
Intervention: Visual inspection by beginners
Number of subjects: 20
Study: 12775666

Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL) program
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no CAL program)
Number of subjects: 67
Study: 11829370

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral anti-emetics (maxolon)
Number of subjects: 8
Study: 9345797

Group type: EXPERIMENTAL
Intervention: Anterior repositioning splint worn 24 hours a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anterior repositioning splint worn during the day or at night
Number of subjects: 0
Study: 7802732

Group type: EXPERIMENTAL
Intervention: Screened group (chest x-ray and sputum cytology every 4 months)
Number of subjects: 10111

Group type: COMPARATOR
Intervention: Control group (annual chest x-ray and cytology recommended)
Number of subjects: 10111

Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 10111

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10111
Study: 3080044

Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate (G)
Number of subjects: 62

Group type: COMPARATOR
Intervention: D-penicillamine (PEN)
Number of subjects: 62
Study: 30143550

Group type: EXPERIMENTAL
Intervention: SRP plus MM
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study: 26782247

Group type: EXPERIMENTAL
Intervention: 100% oxygen via a facemask at a constant flow rate of 3 l/min (O2 group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No supplemental oxygen (Air group)
Number of subjects: 30
Study: 25531191

Group type: EXPERIMENTAL
Intervention: Prelox®R
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22563468

Group type: EXPERIMENTAL
Intervention: Ghrelin (2 µg/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 33
Study: 20478580

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Surveillance with antibiotics only for symptomatic urinary tract infection
Number of subjects: 203
Study: 18703473

Group type: EXPERIMENTAL
Intervention: Transplantation using organs from donors who died from cardiocirculatory causes
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard organ donation
Number of subjects: 3
Study: 17128844

Group type: EXPERIMENTAL
Intervention: One-week amphotericin B (AmB1)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Two-week amphotericin B (AmB2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 57
Study: 12923824

Group type: EXPERIMENTAL
Intervention: Olanzapine plus nizatidine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 35
Study: 10846305

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 42
Study: 9288517

Group type: EXPERIMENTAL
Intervention: Cold antegrade St. Thomas II cardioplegic solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bretschneider cardioplegic solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hamburg cardioplegic solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (baseline samples)
Number of subjects: 30
Study: 8385552

Group type: EXPERIMENTAL
Intervention: Oral tramadol HCL 100 mg (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Multi-vita (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Analgesic containing aspirin 399 mg and codeine phosphate 15 mg (Group C)
Number of subjects: 90
Study: 3943275

Group type: EXPERIMENTAL
Intervention: Intravenous administration of alanine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of alanine
Number of subjects: 0
Study: 31617873

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 100
Study: 30905021

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 28963592

Group type: EXPERIMENTAL
Intervention: High-fat diet with 1.2% betaine supplementation
Number of subjects: 5

Group type: COMPARATOR
Intervention: High-fat diet (HFD)
Number of subjects: 5
Study: 26049730

Group type: EXPERIMENTAL
Intervention: Transvenous vagus nerve stimulation (tVNS) for 30 minutes (0-10 V, 1 ms, 20 Hz) starting 10 minutes before LPS administration (2 ng kg(-1) Escherichia coli lipopolysaccharide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation (no electrical stimulation)
Number of subjects: 20
Study: 23319644

Group type: EXPERIMENTAL
Intervention: Functional connectivity strength (FCS) during resting state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional connectivity strength (FCS) during working-memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-induced changes of FCS and rCBF in the lateral-parietal lobe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rCBF/FCS ratio
Number of subjects: 0
Study: 21746696

Group type: EXPERIMENTAL
Intervention: Intervention (interactive educational workshop, portfolio of practical clinical genetics tools, Gene Messenger)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (standard practice)
Number of subjects: 125
Study: 19455196

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (12 weekly sessions over 3 months)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual treatment in dialysis unit
Number of subjects: 85
Study: 16980747

Group type: EXPERIMENTAL
Intervention: Epoetin alpha (40,000 IU weekly)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard of care (RBV dose reduction from 1000/1200 to 800/600 mg)
Number of subjects: 61
Study: 15531693

Group type: EXPERIMENTAL
Intervention: SFA-rich diet (38% fat - 20% SFA, 12% MUFA, 47% CHO)
Number of subjects: 55

Group type: COMPARATOR
Intervention: CHO-rich diet (30% fat - <10% SFA, 12% MUFA, 55% CHO)
Number of subjects: 55

Group type: COMPARATOR
Intervention: MUFA-rich diet (38% fat - <10% SFA, 22% MUFA, 47% CHO)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: SFA-rich diet
Number of subjects: 55

Group type: COMPARATOR
Intervention: Change from SFA to CHO diet
Number of subjects: 55
Study: 11701734

Group type: EXPERIMENTAL
Intervention: Recombinant human LH (50 IU)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study: 9404792

Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 mg morphine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8517684

Group type: EXPERIMENTAL
Intervention: Myoblast transfer (55 million viable, purified normal myoblasts injected at 55 sites)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Myoblast transfer
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study: 3553135

Group type: EXPERIMENTAL
Intervention: ceftizoxime (2-4 g every 8 h)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: cefotaxime (1-2 g every 4 h)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: latamoxef (2-4 g every 8 h)
Number of subjects: 135
Study: 29106812

Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (WPH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoenergetic carbohydrate (CHO)
Number of subjects: 20
Study: 27183109

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24868083

Group type: EXPERIMENTAL
Intervention: Fixed dose combination treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg with either atenolol 50 mg or hydrochlorothiazide 12.5 mg)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Fixed dose combination treatment
Number of subjects: 513
Study: 22871307

Group type: EXPERIMENTAL
Intervention: Self-inflatable soft tissue expander
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mandibular ramus bone block graft
Number of subjects: 20
Study: 20199139

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg once daily for 16 days, then tapered to 5 mg for 14 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Duloxetine 60 mg once daily for 16 days, then tapered to 30 mg for 14 days
Number of subjects: 34
Study: 18627340

Group type: EXPERIMENTAL
Intervention: Bimatoprost (dosed each evening)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dorzolamide/timolol-fixed combination (DTFC, twice-daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dorzolamide/timolol-fixed combination (DTFC)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 29
Study: 15969661

Group type: EXPERIMENTAL
Intervention: Montelukast 10mg daily in addition to fluticasone 200μg
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Salmeterol 50μg twice daily in addition to fluticasone 200μg
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Asthma patients without concomitant AR (Control)
Number of subjects: 1490
Study: 12121563

Group type: COMPARATOR
Intervention: Low-dose meglumine antimoniate (MA) at 60 mg/kg/day for 20 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination of allopurinol (AL) at 20 mg/kg/day plus low-dose MA at 30 mg/kg/day for 20 days
Number of subjects: 72
Study: 10626305

Group type: EXPERIMENTAL
Intervention: modern active physiotherapy
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: muscle reconditioning on training devices
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: low-impact aerobics
Number of subjects: 148
Study: 7732340

Group type: EXPERIMENTAL
Intervention: Mesalazine suppositories (500 mg, twice daily)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Hydrocortisone foam (178 mg, twice daily)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Mesalazine suppositories
Number of subjects: 79
Study: 1904091

Group type: EXPERIMENTAL
Intervention: Intermittent feeding (5 minutes)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Continuous feeding (2 to 3 hours)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Comparison of intermittent vs continuous feeding
Number of subjects: 11
Study: 6972028

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neck collar
Number of subjects: 30
Study: 30606239

Group type: EXPERIMENTAL
Intervention: LIVE LiFE program (n = 25)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Written fall risk assessment (n = 12)
Number of subjects: 40
Study: 29551560

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice a day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 27358435

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3320

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3320
Study: 24162081

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 23254273

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30-70 mg/d
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) (all doses)
Number of subjects: 41
Study: 21050060

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with SLITone Alternaria, one vial per day for 3 years (n = 34)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 17577644

Group type: EXPERIMENTAL
Intervention: NP101 (iontophoretic sumatriptan patch)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NP101 (iontophoretic sumatriptan patch) delivering 6 and 12 mA per h
Number of subjects: 100

Group type: COMPARATOR
Intervention: 6 mg subcutaneous injection of sumatriptan
Number of subjects: 100

Group type: COMPARATOR
Intervention: 50 mg oral tablet of sumatriptan succinate
Number of subjects: 100
Study: 15734604

Group type: EXPERIMENTAL
Intervention: Premelle 2.5 mg (0.625 mg conjugated estrogen + 2.5 mg medroxyprogestorone)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Kliogest (2 mg estradiol + 1 mg norethisterone)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Livial (2.5 mg tibolone)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Endometrial polyp recurrence
Number of subjects: 375
Study: 12769416

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10084579

Group type: EXPERIMENTAL
Intervention: CYP21 genotyping
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Guthrie cards
Number of subjects: 653
Study: 7582401

Group type: EXPERIMENTAL
Intervention: Fluvastatin (30 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluvastatin (30 mg/day) after niceritrol (750 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Niceritrol (750 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Niceritrol (750 mg/day) after fluvastatin (30 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Niceritrol (750 mg/day) and Fluvastatin (30 mg/day)
Number of subjects: 42
Study: 2210218

Group type: EXPERIMENTAL
Intervention: Phosphate enema
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Glycerin enema
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 100
Study: 508974

Group type: EXPERIMENTAL
Intervention: Helium-oxygen (heliox) mixture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Air
Number of subjects: 24
Study: 31670546

Group type: EXPERIMENTAL
Intervention: Neuropsychological performance assessments (global deficit score, executive-functioning domain, processing-speed domain)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Executive functioning
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Processing-speed performance
Number of subjects: 50
Study: 29702271

Group type: EXPERIMENTAL
Intervention: Hyoscine-N-Butylbromide (HBB) 20 mg
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 29029673

Group type: EXPERIMENTAL
Intervention: Instructed Acceptance
Number of subjects: 193

Group type: COMPARATOR
Intervention: Instructed Suppression
Number of subjects: 193
Study: 26094656

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cisplatin/pemetrexed
Number of subjects: 83
Study: 24207160

Group type: EXPERIMENTAL
Intervention: MDRNSTAT (Physician-Nurse Supplementary Team At Triage)
Number of subjects: 6336

Group type: COMPARATOR
Intervention: Nurse-only triage (Control)
Number of subjects: 6336
Study: 19945757

Group type: EXPERIMENTAL
Intervention: Baseline significant IADL disability
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Baseline significant ADL disability
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Overall functional status
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Predictors of functional decline
Number of subjects: 1164
Study: 18791718

Group type: EXPERIMENTAL
Intervention: Tocosol Paclitaxel (175 mg/m2, 15 min intravenous infusion)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Taxol (175 mg/m2, 3 h intravenous infusion)
Number of subjects: 35
Study: 17458428

Group type: EXPERIMENTAL
Intervention: Tobacco skin prick test
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Bronchial challenge with tobacco
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Delayed bronchial and patch response
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tobacco IgE response (EAST)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: EAST inhibition
Number of subjects: 180
Study: 14726744

Group type: EXPERIMENTAL
Intervention: Immunoglobulin (Ig) therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: No Immunoglobulin (Ig) therapy
Number of subjects: 45
Study: 15831513

Group type: EXPERIMENTAL
Intervention: i.v. fentanyl (100 microg)
Number of subjects: 202

Group type: COMPARATOR
Intervention: i.c. fentanyl (100 microg)
Number of subjects: 202
Study: 10355660

Group type: EXPERIMENTAL
Intervention: Version 6.0
Number of subjects: 46

Group type: COMPARATOR
Intervention: Version 4.7
Number of subjects: 46